Skip to main content
Contact Us
Subscribe
E-Edition
81°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
188.65
+0.39 (+0.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
January 04, 2023
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
December 30, 2022
From
BeiGene
Via
Business Wire
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
December 13, 2022
From
BeiGene
Via
Business Wire
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
December 09, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
November 22, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
November 17, 2022
From
BeiGene
Via
Business Wire
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
November 15, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
November 10, 2022
From
BeiGene
Via
Business Wire
BeiGene Reports Third Quarter 2022 Financial Results
November 09, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
November 04, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
November 03, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
November 02, 2022
From
BeiGene
Via
Business Wire
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
October 26, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
October 14, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
October 12, 2022
From
BeiGene
Via
Business Wire
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
September 19, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
September 19, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
September 10, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 07, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
August 23, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
August 15, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
August 09, 2022
From
BeiGene
Via
Business Wire
BeiGene Reports Second Quarter 2022 Financial Results
August 04, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
July 14, 2022
From
BeiGene
Via
Business Wire
BeiGene Appoints Chan Lee as General Counsel
July 13, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
July 06, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
June 30, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
June 21, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
June 13, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
June 13, 2022
From
BeiGene
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.